ClinicalTrials.gg
TerminatedNCT00574275VANILLAUpdated Jun 7, 2016Results posted

Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer

A Phase 3 interventional study of Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) and Placebo in Pancreatic Neoplasm, sponsored by Sanofi. Terminated at 24 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-07.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Why this study was terminated
Data Monitoring Committee concluded after a planned interim analysis that aflibercept added to gemcitabine would be unable to demonstrate improved survival

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
546
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,851 studies in Pancreatic Neoplasms with a site in United States — 299 open to participants now, 472 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Enrollment
53rd of 1,574
546 · median 37
Started
2007
with 64 others
Phase 3
80 of 1,851
14 open now
Registered
320th of 1,851
by date

Among the 1,851 studies in Pancreatic Neoplasms with a site in United States, this one is the 53rd largest by enrollment of the 1,574 interventional ones that give a count, is one of 65 that started in 2007, is one of 80 in phase 3, and was the 320th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,002 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

299 of the 1,851 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

294 more — sign in →

All 299 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 742 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,851 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The main objective of the study was to evaluate the effectiveness of aflibercept treatment by comparison to placebo in increasing the overall survival (OS) in participants with metastatic pancreatic cancer, treated with gemcitabine.

The secondary objectives were to evaluate progression free survival, clinical benefit, overall response, safety and immunogenicity of aflibercept, in the two treatment arms (Arm 1: Aflibercept and Gemcitabine; Arm 2: Placebo and Gemcitabine).

The study included an interim analysis of OS. In accordance with the study protocol, an interim analysis was performed for the purpose of futility and overwhelming efficacy. On the basis of the interim analysis, the Data Monitoring Committee (DMC) recommended that this study be terminated for futility based on predefined boundary rules.

Read the detailed description

The study included:

  • A screening visit of up to 21 days prior to randomization
  • Randomization at baseline
  • A Treatment period (initiated within 3 days of randomization), which included 28-day treatment cycles in both arms until predefined treatment discontinuation criteria were met
  • A follow-up visit 30 days after discontinuation of treatment,
  • A post study treatment follow-up period until death or the study cutoff date.

The criteria for treatment discontinuation were:

  • Participant (or legal representative) chose to withdraw from treatment
  • The investigator thought that continuation of the study would be detrimental to the participants well-being, such as:

    • Disease progression
    • Unacceptable AEs not manageable by symptomatic therapy, dose delay, or dose modification
    • Intercurrent illness that prevented further administration of study treatment
    • Noncompliance with the study protocol
  • Participant was lost to follow-up
  • Unblinding of the participant's investigational treatment
03

Conditions studied

  • Pancreatic Neoplasm

Keywords

  • metastatic pancreatic cancer
  • angiogenesis inhibitor
  • gemcitabine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or histologically confirmed evidence of epithelial cancer (adenocarcinoma) of the exocrine pancreas
  • disease
  • No prior chemotherapy for pancreatic disease
  • (ECOG) performance status (PS) 0, 1 or 2
  • Adequate renal, liver and bone marrow functions

Exclusion criteria

Exclusion Criteria:

  • Less than 42 days elapsed from prior major surgery (28 days from other prior surgery) to the time of randomization
  • Prior treatment with anti-VEGF or VEGF-Receptor-inhibitors
  • Uncontrolled hypertension
  • Pregnancy or breastfeeding
  • Participant with (M/F) without effective method of

The above information is not intended to contain all considerations relevant to potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
546 participants (actual)

Study arms

  • Placebo comparator
    Placebo and Gemcitabine

    Participants with metastatic pancreatic cancer administered Placebo and 1000 mg/m\^2 Gemcitabine.

    Drug: Placebo · Drug: Gemcitabine

  • Experimental
    Aflibercept and Gemcitabine

    Participants with metastatic pancreatic cancer administered 4 mg/kg Aflibercept and 1000 mg/m\^2 Gemcitabine.

    Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) · Drug: Gemcitabine

Interventions

  • 4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle.

  • DrugPlacebo

    4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle

  • 1000 mg/m\^2 administered IV over 30 minutes on Days 1, 8, 15, and 22 of Cycle 1 (28 days), and then Days 1, 8, and 15 of subsequent 28-day cycles.

    Also known as: Gemzar

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS is the time interval from the date of randomization to the date of death due to any cause. If death was not observed during the study, data on OS were censored at the earlier of the last date participant was known to be alive, or the study data cutoff date (11 September 2009). OS time was estimated from Kaplan-Meier Plots.

    Time frame: From the first randomization until the end of study data cutoff date (approximately 2 years)

Secondary outcomes

  1. Progression Free Survival (PFS) Based on Response Evaluation Criteria in Solid Tumors [RECIST] Criteria

    PFS was the time interval from the date of registration to the date of progression, or death from any cause if it occurs before tumor progression is documented. Tumor progression was assessed using RECIST criteria, by which progression was a pre-defined increase in the size of existing tumors or appearance of one or more new tumors. If a participant did not progress or die, the progression was censored to the date of the last valid tumor assessment or data cut-off, whichever was earlier. Median PFS time was estimated from Kaplan-Meier Plots.

    Time frame: From the first randomization until the end of study data cutoff date (approximately 2 years)

  2. Objective Response Rate (ORR) Assessed by the Investigators According to RECIST Criteria

    Objective response (OR) included complete response \[CR\] and partial response \[PR\]. OR was to be assessed by the Investigators according to RECIST criteria, and confirmed by repeating tumor imaging at least 4 weeks after the first radiological documentation of response. CR would reflect the disappearance of all tumor lesions and PR would reflect a defined reduction of tumor burden. However, OR analysis was not performed, as the study was terminated due to futility.

    Time frame: From the first randomization until the end of the study data cutoff date (approximately 2 years)

  3. Clinical Benefit

    Clinical benefit was to be assessed in all participants by time to symptom worsening (TTSW), evaluated from the time of randomization to symptom worsening, as well as by improvement in tumor related symptoms. However, this analysis was not performed, as the study was terminated due to futility.

    Time frame: From the first randomization until the end of the study data cutoff date (approximately 2 years)

  4. Safety-Number of Participants With Adverse Events (AE)

    All AEs regardless of seriousness or relationship to study treatment, spanning from the signature of informed consent until 30 days after the last administration of study treatment, were recorded. The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported.

    Time frame: up to 30 days after treatment discontinuation. SAEs and related AEs were followed till resolved or stabilized.

  5. Number of Participants With Anti-drug Antibodies

    Anti-drug antibodies in the participants blood sample were detected using a validated immunoassay. The validated lower limit of detection (LLOD) for the assay was about 5.4 ng/mL in the absence of aflibercept and about 25.2 ng/mL in the presence of 20 μg/mL of aflibercept.

    Time frame: Up to 90 days post last dose of study drug

07

Results

Posted Sep 25, 2012
Limitations and caveats
As the study was terminated due to futility, some changes were made to the planned analyses, and the analyses for the following outcome measures were not performed: * Objective Response Rate (ORR) * Clinical Benefit

Participant flow

Between December 2007 and September 2009, a total of 546 participants were randomized in the study: 275 to the placebo group and 271 to the aflibercept group. On the basis of the interim analysis, the Data Monitoring Committee (DMC) recommended that this study be terminated for futility based on predefined boundary rules.

Participant flow — Overall Study
MilestonePlacebo and GemcitabineAflibercept and Gemcitabine
Started275271
Treated273268
Safety population271270
Completed00
Not completed275271
Withdrew: Randomized but not treated23
Withdrew: Adverse event3276
Withdrew: Disease progression160146
Withdrew: Lost to follow-up21
Withdrew: Study stopped based on dmc decision6223
Withdrew: Withdrawal by subject1517
Withdrew: Error calculating tumor measurement10
Withdrew: Physician decision11
Withdrew: Protocol violation01
Withdrew: Patient and investigator decision01
Withdrew: Insurance change01
Withdrew: Operation for curative intent01

Outcome measures

PrimaryOverall Survival (OS)

OS is the time interval from the date of randomization to the date of death due to any cause. If death was not observed during the study, data on OS were censored at the earlier of the last date participant was known to be alive, or the study data cutoff date (11 September 2009). OS time was estimated from Kaplan-Meier Plots.

Time frame:
From the first randomization until the end of study data cutoff date (approximately 2 years)
Reported as:
Median · months
Overall Survival (OS)
monthsPlacebo and GemcitabineAflibercept and Gemcitabine
Overall Survival (OS)7.75 (6.768 to 8.575)6.54 (5.552 to 7.852)
SecondaryProgression Free Survival (PFS) Based on Response Evaluation Criteria in Solid Tumors [RECIST] Criteria

PFS was the time interval from the date of registration to the date of progression, or death from any cause if it occurs before tumor progression is documented. Tumor progression was assessed using RECIST criteria, by which progression was a pre-defined increase in the size of existing tumors or appearance of one or more new tumors. If a participant did not progress or die, the progression was censored to the date of the last valid tumor assessment or data cut-off, whichever was earlier. Median PFS time was estimated from Kaplan-Meier Plots.

Time frame:
From the first randomization until the end of study data cutoff date (approximately 2 years)
Reported as:
Median · months
Progression Free Survival (PFS) Based on Response Evaluation Criteria in Solid Tumors [RECIST] Criteria
monthsPlacebo and GemcitabineAflibercept and Gemcitabine
Progression Free Survival (PFS) Based on Response Evaluation Criteria in Solid Tumors [RECIST] Criteria3.71 (3.515 to 4.567)3.71 (3.450 to 4.468)
SecondaryObjective Response Rate (ORR) Assessed by the Investigators According to RECIST Criteria

Objective response (OR) included complete response \[CR\] and partial response \[PR\]. OR was to be assessed by the Investigators according to RECIST criteria, and confirmed by repeating tumor imaging at least 4 weeks after the first radiological documentation of response. CR would reflect the disappearance of all tumor lesions and PR would reflect a defined reduction of tumor burden. However, OR analysis was not performed, as the study was terminated due to futility.

Time frame:
From the first randomization until the end of the study data cutoff date (approximately 2 years)

No measurements were reported for this outcome.

SecondaryClinical Benefit

Clinical benefit was to be assessed in all participants by time to symptom worsening (TTSW), evaluated from the time of randomization to symptom worsening, as well as by improvement in tumor related symptoms. However, this analysis was not performed, as the study was terminated due to futility.

Time frame:
From the first randomization until the end of the study data cutoff date (approximately 2 years)

No measurements were reported for this outcome.

SecondarySafety-Number of Participants With Adverse Events (AE)

All AEs regardless of seriousness or relationship to study treatment, spanning from the signature of informed consent until 30 days after the last administration of study treatment, were recorded. The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported.

Time frame:
up to 30 days after treatment discontinuation. SAEs and related AEs were followed till resolved or stabilized.
Reported as:
Number · participants
Safety-Number of Participants With Adverse Events (AE)
participantsPlacebo and GemcitabineAflibercept and Gemcitabine
Treatment Emergent Adverse Event (TEAE)257266
Treatment Emergent Serious Adverse Event122148
TEAE leading to death4355
TEAE leading to permanent discontinuation3276
SecondaryNumber of Participants With Anti-drug Antibodies

Anti-drug antibodies in the participants blood sample were detected using a validated immunoassay. The validated lower limit of detection (LLOD) for the assay was about 5.4 ng/mL in the absence of aflibercept and about 25.2 ng/mL in the presence of 20 μg/mL of aflibercept.

Time frame:
Up to 90 days post last dose of study drug
Reported as:
Number · participants
Number of Participants With Anti-drug Antibodies
participantsPlacebo and GemcitabineAflibercept and Gemcitabine
Number of Participants With Anti-drug Antibodies55

Adverse events

Collected over From treatment initiation up to November 26, 2010. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo and Gemcitabine—122/271 (45%)239/271 (88.2%)
Aflibercept and Gemcitabine—148/270 (54.8%)249/270 (92.2%)
Most frequent serious events
Showing 10 of 175
Most frequent serious events
EventPlacebo and GemcitabineAflibercept and Gemcitabine
Disease progressionGeneral disorders25/27138/270
Pulmonary embolismRespiratory, thoracic and mediastinal disorders11/2714/270
Abdominal painGastrointestinal disorders11/2716/270
VomitingGastrointestinal disorders6/27110/270
DehydrationMetabolism and nutrition disorders5/2715/270
CholangitisHepatobiliary disorders4/2715/270
FatigueGeneral disorders5/2711/270
PyrexiaGeneral disorders5/2713/270
AnaemiaBlood and lymphatic system disorders2/2714/270
HypertensionVascular disorders0/2714/270
Most frequent other events
Showing 10 of 32
Most frequent other events
EventPlacebo and GemcitabineAflibercept and Gemcitabine
NauseaGastrointestinal disorders124/271102/270
FatigueGeneral disorders103/27197/270
HypertensionVascular disorders17/27196/270
NeutropeniaBlood and lymphatic system disorders71/27185/270
VomitingGastrointestinal disorders77/27182/270
Weight decreasedInvestigations43/27181/270
Decreased appetiteMetabolism and nutrition disorders72/27178/270
ConstipationGastrointestinal disorders73/27164/270
DiarrhoeaGastrointestinal disorders57/27165/270
Abdominal painGastrointestinal disorders61/27154/270

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo/GemcitabineAflibercept/GemcitabineTotal
Mean60.4 ± 10.062.0 ± 9.461.2 ± 9.7
Age, Customized
Age, Customized(participants)Placebo/GemcitabineAflibercept/GemcitabineTotal
<65 years179161340
>=65 but <75 years7790167
>=75 years192039
Sex/Gender, Customized
Sex/Gender, Customized(participants)Placebo/GemcitabineAflibercept/GemcitabineTotal
Male157160317
Female118111229
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Placebo/GemcitabineAflibercept/GemcitabineTotal
Caucasian/White267256523
Black235
Asian/Oriental3710
Other358
Region of Enrollment
Region of Enrollment(participants)Placebo/GemcitabineAflibercept/GemcitabineTotal
ARGENTINA303
AUSTRIA628
BELGIUM181634
BULGARIA121123
CANADA151631
CHILE8816
CYPRUS336
CZECH REPUBLIC101424
FRANCE111324
GERMANY151025
GREECE5712
HUNGARY71017
INDIA336
ITALY172441
MEXICO123
POLAND121123
PUERTO RICO101
ROMANIA13821
RUSSIAN FEDERATION191938
SLOVAKIA538
SPAIN131427
SWITZERLAND8917
UNITED STATES7068138
Eastern Cooperative Oncology Group (ECOG) Performance Status Score
Eastern Cooperative Oncology Group (ECOG) Performance Status Score(participants)Placebo/GemcitabineAflibercept/GemcitabineTotal
Participants with ECOG Score = 0102102204
Participants with ECOG Score = 1154152306
Participants with ECOG Score = 2191736
Primary tumor resection
Primary tumor resection(participants)Placebo/GemcitabineAflibercept/GemcitabineTotal
Yes403979
No235232467
08

Study locations

24 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis Administrative Office
    Buenos Aires, Argentina
  • Sanofi-Aventis Administrative Office
    Wien, Austria
  • Sanofi-Aventis Administrative Office
    Diegem, Belgium
  • Sanofi-Aventis Administrative Office
    Sofia, Bulgaria
  • Sanofi-Aventis Administrative Office
    Laval, Canada
  • Sanofi-Aventis Administrative Office
    Santiago, Chile
  • Sanofi-Aventis Administrative Office
    Santafe de Bogota, Colombia
  • Sanofi-Aventis Administrative Office
    Nikosia, Cyprus
  • Sanofi-Aventis Administrative Office
    Praha, Czech Republic
  • Sanofi-Aventis Administrative Office
    Paris, France
  • Sanofi-Aventis Administrative Office
    Berlin, Germany
  • Sanofi-Aventis Administrative Office
    Athens, Greece
  • Sanofi-Aventis Administrative Office
    Budapest, Hungary
  • Sanofi-Aventis Administrative Office
    Mumbai, India
  • Sanofi-Aventis Administrative Office
    Milano, Italy
  • Sanofi-Aventis Administrative Office
    Mexico, Mexico
  • Sanofi-Aventis Administrative Office
    Warszawa, Poland
  • Sanofi-Aventis Administrative Office
    Puerto Rico, Puerto Rico
  • Sanofi-Aventis Administrative Office
    Bucuresti, Romania
  • Sanofi-Aventis Administrative Office
    Moscow, Russian Federation
  • Sanofi-Aventis Administrative Office
    Brastislava, Slovakia
  • Sanofi-Aventis Administrative Office
    Barcelona, Spain
  • Sanofi-Aventis Administrative Office
    Geneva, Switzerland
09

References and documents

Publications

  • Rougier P, Riess H, Manges R, Karasek P, Humblet Y, Barone C, Santoro A, Assadourian S, Hatteville L, Philip PA. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. Eur J Cancer. 2013 Aug;49(12):2633-42. doi: 10.1016/j.ejca.2013.04.002. Epub 2013 Apr 30. PubMed 23642329 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Oct 2009 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 2 years 11 months after primary completion. A results delay was requested in Jul 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2007
First posted
Dec 17, 2007
Start
Dec 2007
Primary completionActual
Oct 2009
CompletionActual
Nov 2010
Results delay requested
Jul 21, 2011
Results first posted
Sep 25, 2012
Last update
Jun 7, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00574275
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 17, 2007
Start date
Dec 2007
Primary completion
Oct 2009
Completion
Nov 2010
Results posted
Sep 25, 2012
Last update
Jun 7, 2016

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion